TABLE 1.
Baseline characteristics of patients with ALK‐positive NSCLC treated with crizotinib or alectinib
| Characteristics |
Crizotinib (N = 109) |
Alectinib (N = 59) |
p‐value |
|---|---|---|---|
| Age, years | 53.1 ± 11.9 | 52.0 ± 12.2 | 0.633 |
| Sex | 0.997 | ||
| Male | 61 (56.0%) | 33 (55.9%) | |
| Female | 48 (44.0%) | 26 (44.1%) | |
| ECOG PS | 0.073 | ||
| 0–1 | 92 (84.4%) | 43 (72.9%) | |
| 2–3 | 17 (15.6%) | 16 (27.1%) | |
| Smoke history | 0.435 | ||
| No | 85 (78.0%) | 49 (83.1%) | |
| Yes | 24 (22.0%) | 10 (16.9%) | |
| Histology | 0.795 | ||
| Adenocarcinoma | 105 (96.3%) | 58 (98.3%) | |
| Squamouscarcinoma | 2 (1.8%) | 1 (1.7%) | |
| Others | 2 (1.8%) | 0 (0.0%) | |
| TNM stage | 0.733 | ||
| III | 11 (10.1%) | 5 (8.5%) | |
| IV | 98 (89.9%) | 54 (91.5%) | |
| Extrathoracic metastases | 0.435 | ||
| No | 32 (29.4%) | 14 (23.7%) | |
| Yes | 77 (70.6%) | 45 (76.3%) | |
| Brain metastases | 0.941 | ||
| No | 77 (70.6%) | 42 (71.2%) | |
| Yes | 32 (29.4%) | 17 (28.8%) | |
| Liver metastases | 0.081 | ||
| No | 84 (77.1%) | 52 (88.1%) | |
| Yes | 25 (22.9%) | 7 (11.9%) | |
| Bone metastases | 0.225 | ||
| No | 66 (60.6%) | 30 (50.8%) | |
| Yes | 43 (39.4%) | 29 (49.2%) | |
| Detection method | 0.443 | ||
| IHC | 29 (26.6%) | 19 (32.2%) | |
| NGS | 80 (73.4%) | 40 (67.8%) | |
| 8‐gene | 28 (25.7%) | 7 (11.9%) | |
| 14‐gene | 22 (20.2%) | 16 (27.1%) | |
| 56‐gene | 7 (6.4%) | 6 (10.2%) | |
| 425‐gene | 23 (21.1%) | 11 (18.6%) | |
| VAF, % | 11.6 ± 13.7 | 9.1 ± 10.1 | |
| Fusion type | 0.295 | ||
| EML4‐ALK | 61 (56.0%) | 35 (59.3%) | |
| non‐EML4‐ALK | 10 (9.2%) | 3 (5.1%) | |
| Complex fusion involving EML4‐ALK | 8 (7.3%) | 1 (1.7%) | |
| Unknown | 30 (27.5%) | 20 (33.9%) | |
| Brain radiotherapy | 0.335 | ||
| No | 104 (95.4%) | 58 (98.3%) | |
| Yes | 5 (4.6%) | 1 (1.7%) | |
| CT cycles before or during TKI treatment | <0.001 | ||
| 0 | 59 (54.1%) | 16 (27.1%) | |
| 1 (before TKI) | 22 (20.2%) | 28 (47.5%) | |
| 2 to 6 | 25 (22.9%) | 12 (20.3%) | |
| ≥7 (during TKI) | 3 (2.8%) | 3 (5.1%) |
Abbreviations: CT, Chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; VAF, variant allele fraction.